Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) an open-label randomised phase III trial /
Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced E...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2009
|
| Sorozat: | LANCET
373 No. 9674 |
| Tárgyszavak: | |
| doi: | 10.1016/S0140-6736(09)60569-9 |
| mtmt: | 3410577 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/30003 |